|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.10 GBX | -.--% |
|
+6.42% | +9.39% |
| Apr. 21 | British Land raises earnings guidance after Life Science REIT deal | AN |
| Apr. 21 | Stocks rise, British Land forecasts guidance beat | AN |
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Profitability | ||||
Return on Assets | - | 0.82 | 1.25 | 1.48 |
Return on Total Capital | - | 0.85 | 1.31 | 1.54 |
Return On Equity % | - | -8.24 | -7.2 | -5.11 |
Return on Common Equity | - | -8.24 | -7.2 | -5.11 |
Margin Analysis | ||||
Gross Profit Margin % | 100 | 69.64 | 69.33 | 71.03 |
SG&A Margin | 156.77 | 35.71 | 26.32 | 23.82 |
EBITA Margin % | -56.77 | 33.93 | 43 | 47.2 |
EBIT Margin % | -56.77 | 33.93 | 43 | 47.2 |
Income From Continuing Operations Margin % | 1.46K | -175.81 | -108.85 | -68.82 |
Net Income Margin % | 1.46K | -175.81 | -108.85 | -68.82 |
Net Avail. For Common Margin % | 1.46K | -175.81 | -108.85 | -68.82 |
Normalized Net Income Margin | -34.66 | 19.11 | 8.71 | 10.46 |
Levered Free Cash Flow Margin | - | -45.79 | -119.99 | -95.55 |
Unlevered Free Cash Flow Margin | - | -30.74 | -89.9 | -63.57 |
Asset Turnover | ||||
Asset Turnover | - | 0.04 | 0.05 | 0.05 |
Fixed Assets Turnover | - | 0.05 | 0.05 | 0.05 |
Receivables Turnover (Average Receivables) | - | 14.85 | 9.68 | 7.44 |
Short Term Liquidity | ||||
Current Ratio | 15.64 | 1.06 | 1.45 | 0.98 |
Quick Ratio | 15.51 | 0.99 | 1.29 | 0.89 |
Operating Cash Flow to Current Liabilities | 0.78 | -0.02 | 0.53 | 1.05 |
Days Sales Outstanding (Average Receivables) | - | 24.59 | 37.7 | 49.21 |
Long Term Solvency | ||||
Total Debt/Equity | - | 34.38 | 38.03 | 46.52 |
Total Debt / Total Capital | - | 25.58 | 27.55 | 31.75 |
LT Debt/Equity | - | 23.19 | 38.03 | 46.52 |
Long-Term Debt / Total Capital | - | 17.26 | 27.55 | 31.75 |
Total Liabilities / Total Assets | 2.99 | 28.67 | 30.91 | 34.5 |
EBIT / Interest Expense | - | 1.41 | 0.89 | 0.92 |
Growth Over Prior Year | ||||
Total Revenues, 1 Yr. Growth % | - | 1.13K | 26.97 | 1.84 |
Gross Profit, 1 Yr. Growth % | - | 756.59 | 26.41 | 4.33 |
EBITA, 1 Yr. Growth % | - | -835.24 | 60.93 | 11.62 |
EBIT, 1 Yr. Growth % | - | -835.24 | 60.93 | 11.62 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | -248.63 | -21.39 | -35.61 |
Net Income, 1 Yr. Growth % | - | -248.63 | -21.39 | -35.61 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | -249.62 | -21.5 | -35.5 |
Normalized Net Income, 1 Yr. Growth % | - | -778.25 | -42.11 | 21.74 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 101.67 | -1.35 | 0.76 |
Accounts Receivable, 1 Yr. Growth % | - | 78.43 | 82.26 | 12.98 |
Total Assets, 1 Yr. Growth % | - | 23.91 | -8.29 | -2.32 |
Common Equity, 1 Yr. Growth % | - | -8.88 | -11.18 | -7.39 |
Tangible Book Value, 1 Yr. Growth % | - | -8.88 | -11.18 | -7.39 |
Cash From Operations, 1 Yr. Growth % | - | -112.81 | -799.91 | 69.68 |
Capital Expenditures, 1 Yr. Growth % | - | - | 214.54 | -19.78 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 232.71 | -18.88 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 271.28 | -27.95 |
Dividend Per Share, 1 Yr. Growth % | - | - | -50 | -50 |
Compound Annual Growth Rate Over Two Years | ||||
Total Revenues, 2 Yr. CAGR % | - | - | 295.21 | 13.71 |
Gross Profit, 2 Yr. CAGR % | - | - | 229.06 | 14.84 |
EBITA, 2 Yr. CAGR % | - | - | 243.98 | 34.12 |
EBIT, 2 Yr. CAGR % | - | - | 243.98 | 34.12 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 8.09 | -28.85 |
Net Income, 2 Yr. CAGR % | - | - | 8.09 | -28.85 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | 8.38 | -28.84 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 98.16 | -15.87 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 41.05 | -0.3 |
Accounts Receivable, 2 Yr. CAGR % | - | - | 80.33 | 43.5 |
Total Assets, 2 Yr. CAGR % | - | - | 6.6 | -5.35 |
Common Equity, 2 Yr. CAGR % | - | - | -10.04 | -9.3 |
Tangible Book Value, 2 Yr. CAGR % | - | - | -10.04 | -9.3 |
Cash From Operations, 2 Yr. CAGR % | - | - | -5.3 | 244.61 |
Capital Expenditures, 2 Yr. CAGR % | - | - | - | 58.85 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 64.26 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 63.52 |
Dividend Per Share, 2 Yr. CAGR % | - | - | - | -50 |
Compound Annual Growth Rate Over Three Years | ||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 151.49 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 124.38 |
EBITA, 3 Yr. CAGR % | - | - | - | 136.49 |
EBIT, 3 Yr. CAGR % | - | - | - | 136.49 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | -9.05 |
Net Income, 3 Yr. CAGR % | - | - | - | -9.05 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -8.84 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 68.7 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 26.09 |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 54.31 |
Total Assets, 3 Yr. CAGR % | - | - | - | 3.54 |
Common Equity, 3 Yr. CAGR % | - | - | - | -9.16 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | -9.16 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 15.02 |
- Stock Market
- Equities
- LABS Stock
- Financials Life Science REIT plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















